Brady W. Dougan Sells 427,459 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Humacyte Price Performance

HUMA stock traded down $0.01 during trading on Wednesday, reaching $4.41. 2,094,875 shares of the company were exchanged, compared to its average volume of 2,412,612. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. The stock’s 50 day moving average price is $5.38 and its 200 day moving average price is $6.20. Humacyte, Inc. has a 52-week low of $2.43 and a 52-week high of $9.97. The company has a market cap of $555.04 million, a P/E ratio of -3.29 and a beta of 1.47.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently modified their holdings of the company. State Street Corp raised its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after buying an additional 179,120 shares during the last quarter. Millennium Management LLC boosted its position in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Humacyte by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after acquiring an additional 66,946 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of recent research reports. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Humacyte in a report on Wednesday, November 13th. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.